Immunic, inc. reports third quarter 2021 financial results and highlights recent activity

New york, nov. 4, 2021 /prnewswire/ -- immunic, inc.  (nasdaq: imux), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced financial results for the third quarter ended september 30, 2021 and highlighted recent activity. "during the quarter, we continued to make extraordinary progress advancing multiple programs through the clinic, including our selective oral dhodh inhibitor, imu-838, as well as imu-935, a highly potent and selective oral il-17 inhibitor, setting the stage for an exciting year ahead with several upcoming value creating data readouts," stated daniel vitt, ph.d.
IMUX Ratings Summary
IMUX Quant Ranking